Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.42 |
| ▸ | RELA | Q04206 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HPGDS | O60760 | 10/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21397962 | 0.86 | NPC1 (0.44) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL18015292 | 0.85 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2IDO1TDO2 | |
| SCHEMBL21202848 | 0.83 | IDO1 (0.44) | NPC1RAB9ASMN1; SMN2IDO1TDO2 | |
| SCHEMBL21398063 | 0.82 | HPGDS (0.46) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL18015492 | 0.81 | LDHA (0.44) | NPC1RAB9ASMN1; SMN2HPGDSIDO1 | |
| SCHEMBL19834634 | 0.81 | ADORA2A (0.39) | NPC1RAB9ASMN1; SMN2IDO1TDO2 | |
| SCHEMBL21125093 | 0.81 | LDHA (0.44) | NPC1RAB9ASMN1; SMN2HPGDSIDO1 | |
| SCHEMBL18015599 | 0.81 | LDHA (0.44) | NPC1RAB9ASMN1; SMN2HPGDSIDO1 | |
| SCHEMBL23956184 | 0.80 | LDHA (0.42) | NPC1RAB9ASMN1; SMN2HPGDSIDO1 | |
| SCHEMBL19794464 | 0.80 | LDHA (0.42) | NPC1RAB9ASMN1; SMN2HPGDSIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136343-B2 | Binuclear metal complexes for use as emitters in organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2021-10-05 | — | — | US | disclosed |
| EP-3515925-B1 | BINUCLEAR METAL COMPLEXES FOR USE AS EMITTERS IN ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2020-10-21 | — | — | EP | disclosed |
| US-20190292210-A1 | BINUCLEAR METAL COMPLEXES FOR USE AS EMITTERS IN ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292210-A1 | BINUCLEAR METAL COMPLEXES FOR USE AS EMITTERS IN ORGANIC ELECTROLUMINESCENT DEVICES | AP2M1, MCU, AP3M1 | NPC1 3230/4885NFKB1 2713/4885RAB9A 1967/4885 |
| US-11136343-B2 | Binuclear metal complexes for use as emitters in organic electroluminescent devices | AP2M1, MCU, AP3M1 | NPC1 3230/4885NFKB1 2713/4885RAB9A 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.